September 1, 1998Clinical and Experimental Pharmacology and Physiology
Restoration of Nitric Oxide Function in Human Hyperlipidaemia, Congestive Heart Failure and Liver Cirrhosis
Population
Patients with hyperlipidaemia, congestive heart failure, or liver cirrhosis
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Highlights potential for NO pathway modulation in cardiohepatic disease; leaves open translation of reviewed strategies to clinical practice.
Structured PICO
P
Population
Patients with hyperlipidaemia, congestive heart failure, or liver cirrhosis
I
Intervention
Pharmacological (lipid-lowering therapy, ACE inhibitors, antibiotics) and non-pharmacological (exercise, L-arginine, n-3 polyunsaturated fatty acids) interventions to correct disturbed nitric oxide signalling
This review summarizes the evidence for nitric oxide signaling abnormalities in cardiovascular and hepatic diseases and outlines pharmacological and non-pharmacological strategies for their correction.
Cite This Study
Chin‐Dusting et al. (1998) studied this question.